1Tan EM,Cohen AS,Fries JF,et al.The 1982 revised criteria for the classification of systemic lupus enythematosus[J].J Rheumatol,1982,25:1271.
2Najafi CC,Korbet SM,Lewis EJ,et al.Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis[J].Kidney International,2001,59:2156-2163.
3Cortes HJ,Ordi RJ,Labrador M,et al.Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone[J].Lupus,2003,12:287-296.
4Illei GG,Takada K,Parkin D,et al.Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy[J].Arthritis Rheum,2002,46:256-264.
5Boumpas DT,Austin HA,Vaughn EM,et al.Controlled trial of pluse methylpredisolone versus two regimens of pulse CYC in severe lupus nephritis[J].Lancet,1992,340:741-745.
7Fu LW,Yang LY,Chen WP,et al.Clinical efficacy of cyclosporin A Neoral in the treatment of paediatric lupus nephritis with heavy proteinuria[J].British Journal of Rheumatology,1998,37:217-221.
9Caccavo D,Lagana B,Mitterhofer AP,et al.Long-term treatment of systemic lupus erythematosus with cyclosporin A[J].Arthritis Rheum,1997,40:27-53.
10Houssiau FA,Vasconcelos C,D′Cruz D,et al.Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis:lessons from long-term follow-up of patients in the Euro-Lupus Nephritis Trial[J].Arthritis Rheum,2004,50:3934-3940.
二级参考文献8
1Austin HA,Klippel JH,Balow JE,et al.Therapy of lupus nephritis.controlled trial of prednisone and cytotoxic drugs. N Engl J Med, 1986,314(10):614-619.
2Mok CC, Ho CT, Siu YP,et al.Treatment of diffuse proliferative lupus glomerulonephritis:a comparison of two cyclophospharmde-containing regimens. Am J Kidney Dis, 2001,38: 256-257.
3Barbano G,Gusmano R,Damasio B.Childhood- onset lupus nephritis:a single- center experience of pulse intravenous cyclophosphamide therapy.J Nephrol, 2002,15:123-129.
4Jonsson C,Carlsten H.Mycophenolic acid inhibits inosine 5(')monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines ,nitric oxide ,and LDH in macrophages. Cell Immunol, 2002,216: 93-95.
5Dooley MA,Chiso FO,Nachman PR,et al. Mycophenolate mofetil therapy in lupus nephritis:clinical observations.J Am Soc Nephrol, 1999,10:1-3.
6Gescuk BD,Davis JC Jr. Novel therapeutic agents for systemic lupus erythematosus. Curr Opin Rheumatol,2002,14:515 -521.
7Mok CC,Lai KN.Mycophenolate mofetil in lupus glomerulonephritis. Am J Kidney Dis,2002,40:447-457.
8Houssiau FA, Vasconcelos C, D' Cruz D, et al.Immunosuppressive therapy in lupus nephritis:the Euro-Lupus Nephritis Trial,a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum,2002,46:2121-2131.
6Mak A, Mok CC, Chu WP, et al. Renal damage in systemic lupus er- ythematosus : a comparative analysis of different age groups [ J ]. Lu- pus, 2007, 16 (1): 28-34.
7Pollak VE, Pirani CL, Sschwartz FD. The natural history of the renal manifestations of systemic lupus erythematosus [ J ]. J Lab Clin Med, 1964, 63: 537-550.
8Favre H, Miescher PA, Huang YP, et al. Cyclosporin in the treatment of lupus nephritis [J]. Am J Nephrol, 1989, 9 (Suppl) : 57 -60.
9Ogawa H, Kameda H, Nagasawa H, et al. Prospective study of low - dose cyclosporine A in patients with refractory lupus nephritis [ J]. Mod Rheumatol, 2007, 17 (2) : 92 -97.
10Balletta M, Sabella D, Magri P, et al. Ciclosporin plus steroids versus steroids alone in the treatment of lupus nephritis [ J ]. Contributions to Nephrology, 1992, 99:129 - 130.
